KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation & Amortization - Total: 2009-2021

Historic Depreciation & Amortization - Total for Arbutus Biopharma (ABUS) over the last 12 years, with Sep 2021 value amounting to $447,000.

  • Arbutus Biopharma's Depreciation & Amortization - Total fell 8.78% to $447,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $1.8 million, marking a year-over-year decrease of 9.26%. This contributed to the annual value of $2.0 million for FY2020, which is 2.47% down from last year.
  • As of Q3 2021, Arbutus Biopharma's Depreciation & Amortization - Total stood at $447,000, which was up 2.52% from $436,000 recorded in Q2 2021.
  • Arbutus Biopharma's Depreciation & Amortization - Total's 5-year high stood at $620,000 during Q4 2017, with a 5-year trough of $334,000 in Q1 2017.
  • For the 3-year period, Arbutus Biopharma's Depreciation & Amortization - Total averaged around $484,727, with its median value being $500,000 (2020).
  • In the last 5 years, Arbutus Biopharma's Depreciation & Amortization - Total surged by 103.78% in 2017 and then dropped by 18.71% in 2018.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Depreciation & Amortization - Total stood at $620,000 in 2017, then fell by 18.71% to $504,000 in 2018, then climbed by 0.60% to $507,000 in 2019, then dropped by 3.94% to $487,000 in 2020, then declined by 8.78% to $447,000 in 2021.
  • Its Depreciation & Amortization - Total was $447,000 in Q3 2021, compared to $436,000 in Q2 2021 and $443,000 in Q1 2021.